"10.1371_journal.ppat.1002793","plos pathogens","2012-07-05T00:00:00Z","Youssif M Ali; Nicholas J Lynch; Kashif S Haleem; Teizo Fujita; Yuichi Endo; Soren Hansen; Uffe Holmskov; Kazue Takahashi; Gregory L Stahl; Thomas Dudler; Umakhanth V Girija; Russell Wallis; Aras Kadioglu; Cordula M Stover; Peter W Andrew; Wilhelm J Schwaeble","Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom; Faculty of Pharmacy, University of Mansoura, Mansoura, Egypt; Department of Immunology, Fukushima Medical University, Fukushima, Japan; Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark; Department of Anesthesiology, Perioperative and Pain Medicine, Harvard Medical School, Boston, Massachusetts, United States of America; Omeros Corporation, Seattle, Washington, United States of America","Â¤ Current address: Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom","I have read the journals policy and have the following conflicts: Thomas Dudler is an employee of Omeros Inc., which aims to market anti-MASP-2 monoclonal antibodies for therapeutic use. Thomas Dudler, Wilhelm J. Schwaeble, Cordula M. Stover and Teizo Fujita are named inventors on patents held by the University of Leicester, protecting the I.P. behind the therapeutic application of MASP-2 specific inhibitors for treating lectin pathway mediated inflammatory pathologies. This does not alter our adherence to all PLoS Pathogens policies on sharing data and materials.","2012","07","Youssif M Ali","YMA",16,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
